Seventeen years later, NxStage founder & CEO Jeff Burbank’s hypothesis has proven out. His Lawrence, Mass.-based company is topping more than $300 million in annual sales and, more importantly, is making a real difference in the everyday lives of dialysis patients.
NxStage took on some of the biggest names in medtech along the way and managed to beat them back, as evidenced by Baxter‘s (NYSE:BAX) decision to pull the plug on its competing Vivia home hemodialysis device. And Burbank has remained firmly in place as the founding CEO, a rarity in a medical device world, where founders are usually replaced after the development phase in favor of a more seasoned executive.
In this interview, recorded at MassDevice.com’s DeviceTalks Boston event Sept. 28, we sat down with Jeff to discuss how he’s kept his focus over nearly 2 decades as a founder & chief executive and his game-changing vision to improve the lives of dialysis patients.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.